Herceptin

Mylan NV (NASDAQ: MYL)’s had a rough three years, but one analyst left the pharma company's investor day with fresh optimism. The Rating Leerink analyst Ami Fadia upgraded Mylan from Market Perform to Outperform and maintained a $52 price target. The Thesis By Leerink’s...

“While new approvals hurt Mylan N.V. (NASDAQ: MYL) on price (during Q3), the company has defended share effectively; a point management highlighted but we believe has been underappreciated,” Barclays’ Douglas D. Tsao said in a note. The analyst maintains an Equal-Weight rating on...